

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/757,992	01/10/2001	Gary A. Schultz	200701/1061	8517
75	90 07/03/2002			
Michael L. Goldman NIXON PEABODY LLP Clinton Square P.O. Box 31051			EXAMINER	
			SISSON, BRADLEY L	
Rochester, NY 14603			ART UNIT	PAPER NUMBER
			1634	12
			DATE MAILED: 07/03/2002	15

Please find below and/or attached an Office communication concerning this application or proceeding.

· 	Application No.	Applicant(s)				
Office Action Summer	09/757,992	SCHULTZ ET AL.				
Office Action Summary	Examiner	Art Unit				
	Bradley L. Sisson	1634				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	66(a). In no event, however, may a rep within the statutory minimum of thirty rill apply and will expire SIX (6) MONTI cause the application to become ABA	ly be timely filed (30) days will be considered timely. 4S from the mailing date of this communication. NDONED (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>09 h</u>	<u> 1ay 2002</u> .					
2a) This action is FINAL . 2b) ☐ Thi	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under language of Claims	Ex paπe Quayle, 1935 C.D.	. 11, 453 O.G. 213.				
4)⊠ Claim(s) <u>1-53</u> is/are pending in the application.						
4a) Of the above claim(s) <u>21-53</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-20</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14)⊠ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 8	5) Notice of In	ummary (PTO-413) Paper No(s) · formal Patent Application (PTO-152)				

Application/Control Number: 09/757,992

Art Unit: 1634

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-20, in Paper No. 12 is acknowledged. The traversal is on the ground(s) that the inventions are closely related and would require common areas of search and consideration. This is not found persuasive because the electrospray system of claim 22 does not require a search of the reagents found in Group III, claim 48.

The requirement is still deemed proper and is therefore made FINAL.

2. Claims 21-53 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 12, received 09 May 2002.

Claim Rejections - 35 USC § 112

- 3. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 4. Claims 1-20 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. As presently worded, one is to detect single nucleotide polymorphisms. For purposes

of examination, the claims have been interpreted as (a) encompassing all single nucleotide polymorphisms in a nucleic acid of any length; (b) that a heterogeneous mixture of nucleic acids may be present and that single nucleotide polymorphisms present on any or all of the nucleic acid sequences are to be detected; (c) that the primers do not need to anneal immediately adjacent to the site suspected of undergoing change, but that they can hybridize at virtually distance away from the suspected site(s); (d) that the analogs added or used in the reaction do not need to be chain terminating nucleotides (claim 2 is excluded from this issue); (e) that the nucleic acid amplification sample may be a crude biological sample wherein are found contaminants that could plug an electrospray apparatus; (f) that the nucleic acid being studied, and primers, can be RNA and that the reaction utilizes an RNA polymerase; and (g) encompassing but a single round of primer extension with an infinitely dilute sample of target nucleic acid whereby one would be attempting to detect the usage of but a single molecule of nucleotide analog.

5. The specification does not set forth in sufficient detail how one of skill in the art would be able to practice the claimed invention, in a reproducible manner, to the fullest extent of the claims' scope, including the embodiments identified in a-g, above. In view of the limits of technology, the variability of the assay conditions, ad the unpredictability of the art, one of skill in the art would have to resort to routine experimentation of an indeterminable length, with little expectation of success. In support of this position, it is noted that, as here, where the technology is directed to an area of art that is unpredictable, such as matters of chemistry, which border on physiological systems, greater levels of enablement are required. As noted in *In re Fisher* 166 USPQ 18 (CCPA, 1970):

In cases involving predictable factors, such as that, once imagined, other embodiments can be made without difficulty and their performance characteristics predicted by resort

Application/Control Number: 09/757,992 Page 4

Art Unit: 1634

to known scientific laws. In cases involving unpredictable factors, such as most chemical reactions and physiological activity, the scope of enablement obviously varies inversely with the degree of unpredictability of the factors involved.

The amount of effort required on the part of the skilled artisan, assuming that enablement of the full scope of the invention could somehow, someday be achieved, is a most daunting task, and is considered to rise to the level of undue experimentation.

6. For the above reasons, and in the absence of convincing evidence to the contrary, the specification has not been found to fully enable the claimed method.

Conclusion

- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bradley L. Sisson whose telephone number is (703) 308-3978. The examiner can normally be reached on 6:30 a.m. to 5 p.m., Monday through Thursday.
- 8. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones can be reached on (703) 308-1152. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Page 5

Art Unit: 1634

Any inquiry of a general nature or relating to the status of this application or proceeding 9. should be directed to the receptionist whose telephone number is (703) 308-0196.

> Bradley L. Sisson Primary Examiner Art Unit 1634

B. L. Sisson

BLS July 1, 2002